DLL3 and small cell lung carcinoma: A BiTE that specifically targets DLL3 has the potential to selectively direct T cells against SCLC cells, thereby offering an innovative treatment modality that may overcome the constraints of conventional therapies and fulfill the substantial need for more effective SCLC treatments.